Dashboard
With a growth in Net Sales of 452.24%, the company declared Very Positive results in Jun 25
- OPERATING CASH FLOW(Y) Highest at USD -7.05 MM
- ROCE(HY) Highest at -29.28%
- RAW MATERIAL COST(Y) Fallen by -1.48% (YoY)
With ROE of -83.25%, it has a risky valuation with a 1.87 Price to Book Value
MFs have decreased holdings this quarter and now hold 2.17% of the company
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
USD 94 Million (Micro Cap)
NA (Loss Making)
NA
3.16%
-0.32
-62.05%
1.07
Total Returns (Price + Dividend) 
Dominari Holdings, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
Is Dominari Holdings, Inc. technically bullish or bearish?
As of 9 September 2025, the technical trend for Dominari Holdings, Inc. has changed from bullish to mildly bullish. The weekly MACD indicates a bullish stance, while the monthly MACD is mildly bullish. The daily moving averages are bullish, supporting a positive short-term outlook. However, the monthly RSI is bearish, suggesting potential weakness. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, indicating some upward momentum. The KST shows a mixed signal with weekly mildly bearish and monthly bullish readings. Overall, the technical stance is mildly bullish, but with caution due to the bearish monthly RSI. Multi-period return data is not available for comparison with the S&P 500....
Read MoreIs Dominari Holdings, Inc. overvalued or undervalued?
As of 6 November 2023, the valuation grade for Dominari Holdings, Inc. has moved from does not qualify to risky. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 1.87, an EV to Sales ratio of 2.45, and a troubling ROCE of -169.94%. In comparison to peers, Dominari's EV to EBITDA stands at -1.51, while Frequency Therapeutics, Inc. shows a slightly better EV to EBITDA of -1.0091, indicating that Dominari is lagging behind in operational efficiency. The stock's current price of 6.33 is significantly below its 52-week high of 13.58, suggesting volatility and potential investor concerns. Although specific return data is not available, the lack of positive performance metrics reinforces the notion that Dominari Holdings is overvalued in the current market context....
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 5 Schemes (2.17%)
Held by 5 Foreign Institutions (0.15%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is 450.00% vs 6,100.00% in Jun 2024
YoY Growth in quarter ended Jun 2025 is 390.16% vs 29.89% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 805.00% vs 0.00% in Dec 2023
YoY Growth in year ended Dec 2024 is 35.81% vs -3.62% in Dec 2023






